Interim report January – March 2023 for CombiGene AB (publ)

MARKN.

January – March 2023
• Net sales: TSEK 2,168 (11,403).
• Other operating revenues: TSEK 0 (2,801).
• Profit from financial items: TSEK -14,617 (2,684).
• Earnings per share: SEK -0.74 (0.14).
• Cash and cash equivalents: TSEK 120,506 (121,665).

Events during the period
• CombiGene entered into a collaboration agreement with the Danish company Zyneyro for the development of a unique concept for effective relief of chronic pain. The agreement with Zyneyro is a cooperation agreement that means that Zyneyro and CombiGene share the project’s costs and revenues equally. According to the agreement CombiGene has paid Zyneyro an upfront of DKK 5 million in connection with the signing of the agreement. CombiGene has furthermore committed to pay an additional maximum of DKK 11.4 million in continued development support towards a clinical study in Phase 1.
• Doctoral dissertation at the University of Copenhagen confirms the pain-relieving effect of COZY01 and COZY02 in experimental models.

Events after the end of the period
• Gene Therapy, one of Nature’s journals, publishes an article about CombiGene’s epilepsy project authored by Esbjörn Melin, researcher at CombiGene.

About CombiGene

CombiGene’s vision is to offer patients affected by severe life‐changing diseases opportunities for a better life through innovative gene therapies. CombiGene’s business concept is to develop effective gene therapies for serious diseases that today lack adequate treatment methods. Research assets are taken in from a network of external researchers and developed further up to preclinical/clinical concept verification. Drug candidates for common diseases will be co‐developed and commercialized through strategic partnerships, while CombiGene may drive the development and commercialization in‐house for medicines aimed at limited patient populations.

The company has an exclusive collaboration and license agreement with Spark Therapeutics for the CG01 project and a collaboration agreement with the Danish company Zyneyro within the pain program COZY.

The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, info@fnca.se.

CombiGene’s lead project CG01 has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 823282.
CombiGene´s project CGT2 is supported by the Eurostars Programme. Project ID: 114714

Datum	2023-05-12, kl 08:00
Källa	MFN

Bifogade filer

CombiGene Q1 2023 ENG

Hej Serverägare! Har du problem med troll och spam? Nu finns möjligheten att sätta en liten avgift, t.ex. 20kr, på discord invites och därmed stoppa många återkommande troll samtidigt som du tjänar lite pengar. Kolla in Invite Paywall.

LOGGA IN

Combigene

Interim report January – March 2023 for CombiGene AB (publ)